AngioDynamics (Queensbury, New York), a wholly owned subsidiary of E-Z-EM (Westbury, New York), has entered into a worldwide agreement with Transonic Systems (Ithaca, New York) for distribution of the Transonic Endovascular Flowmeter System. The system will be marketed under the AngioDynamics brand name and consists of the AngioDynamics Flowmeter and the Reo-Cath Dilution Flow Catheter. Under the terms of the five-year agreement, AngioDynamics will distribute both products globally, with exclusive rights in the U.S. The products have been previously cleared by the FDA and comparable international agencies. The Flowmeter system measures flow rates in the bloodstream, providing physicians with the means to monitor the success of interventional vascular procedures such as hemodialysis catheter placement, stenting procedures, and peripheral balloon angioplasty. AngioDynamics is a supplier of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and therapeutic treatment of peripheral vascular disease. Transonic makes instruments that measure blood flow for scientists and healthcare professionals.
Predictive medicine company International Medical Innovations (IMI; Toronto, Ontario) said it has expanded its marketing partnership with McNeil Consumer Healthcare (Guelph, Ontario) to include the laboratory market for insurance testing throughout the U.S., Canada and Mexico. "The market for insurance testing represents a significant new opportunity for our predictive heart disease test throughout North America," said Dr. Brent Norton, IMI president and CEO. IMI is a developer of rapid, noninvasive tests for the early detection and monitoring of life-threatening diseases, particularly cardiovascular disease and cancer.
International Technidyne (ITC; Edison, New Jersey), a subsidiary of Thoratec (Pleasanton, California), has signed an agreement with Sulzer Carbomedics (Austin, Texas), a developer of mechanical heart valves, to co-market ITC's ProTime blood coagulation testing system to cardiothoracic surgeons in the U.S. Carbomedics sales representatives will promote the ProTime system to surgeons who implant mechanical heart valves. The ITC sales force will train Carbomedics reps on the ProTime system and, on occasion, accompany them on sales calls. According to ITC president Lawrence Cohen, joining forces with Carbomedics enables ITC to reach cardiothoracic surgeons who make the initial determination on how their patients' blood coagulation levels will be monitored. "Now that home coagulation testing is covered by Medicare for mechanical heart valve patients, we have a unique opportunity to educate surgeons about the clinical benefits of home testing, the patient convenience and compliance advantages, and the resultant cost savings," he said. Originally introduced as a professional-use device, ProTime became the first FDA cleared system for patient self-testing. ProTime tests are performed in laboratories, physicians' offices, anticoagulation therapy clinics and the home. The system consists of a small, battery-powered instrument and a disposable cuvette. Just one drop of blood from a fingerstick is needed to perform a test, and the system provides results in minutes. Sulzer Carbomedics is a a subsidiary of Centerpulse (Zurich, Switzerland).
Possis Medical (Minneapolis, Minnesota) said it has received a two year contract extension for thrombectomy supplies and equipment from HealthTrust Purchasing Group (HPG; Brentwood, Tennessee), which manages about $5 billion in annual purchasing volume on behalf of its member facilities. The contract extension runs through Dec. 31, 2004. Possis also said that Novation (Irving, Texas) has awarded the company a two year contract to supply thrombectomy management products to VHA and University HealthSystem Consortium members. The contract award runs through Nov. 15, 2004, and represents a follow-on award to the company's original contract with Novation that was signed in October 1999. Possis Medical makes medical devices for the cardiovascular and vascular treatment markets.
Welch Allyn Monitoring (Beaverton, Oregon) and Mortara Instrument (Milwaukee, Wisconsin) have signed a licensing agreement that provides Welch Allyn Monitoring with access to Mortara Instrument's Veritas cardiology technology for its Flexible Monitoring care products. "The inclusion of Mortara's world-class cardiac arrhythmia recognition capability, along with soon-to-be released enhanced tools, will enable us to become an even stronger player in the cardiac arena," said Rick Davis, vice president of marketing for Welch Allyn Monitoring. The licensing agreement allows for the integration of Mortara's Veritas ECG signal processing algorithms into Welch Allyn Monitoring's Acuity Central Monitoring Station. Both Mortara's Arrhythmia Analysis algorithm and ST Analysis algorithm will be included in the new software release. The Acuity Central Monitoring Station offers the centralization of essential vital sign parameters such as blood pressure, temperature, pulse oximetry and capnography on one system. Welch Allyn Monitoring said it expects to begin shipments of the Acuity Central Monitoring System with version 5.40 software immediately. Operated through Welch Allyn Protocol, a wholly owned subsidiary of Welch Allyn (Skaneatelles Falls, New York), Welch Allyn Monitoring designs monitoring solutions that improve patient care and lower healthcare operating costs. Mortara designs products for the noninvasive cardiology field.